111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
111 Stock Performance
YI traded down $0.10 during midday trading on Wednesday, hitting $8.08. The stock had a trading volume of 8,687 shares, compared to its average volume of 24,517. The company has a market cap of $69.84 million, a P/E ratio of -2.02 and a beta of 0.47. The business has a fifty day moving average of $7.86 and a 200 day moving average of $7.58. 111 has a 1 year low of $4.15 and a 1 year high of $12.90.
111 (NASDAQ:YI - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $527.14 million during the quarter.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after purchasing an additional 305,339 shares in the last quarter. FIL Ltd bought a new position in 111 in the 4th quarter worth $450,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in 111 in the 1st quarter worth $92,000. Deuterium Capital Management LLC bought a new position in 111 in the 1st quarter worth $81,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd bought a new position in 111 in the 4th quarter worth $245,000. 21.32% of the stock is currently owned by institutional investors.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Read More
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
